Dr. Reddy’s Laboratories (RDY) Set to Announce Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.86 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Dr. Reddy’s Laboratories Stock Up 0.6 %

RDY opened at $75.21 on Monday. The firm’s 50-day simple moving average is $73.97 and its 200-day simple moving average is $70.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55. Dr. Reddy’s Laboratories has a twelve month low of $53.12 and a twelve month high of $77.72. The firm has a market cap of $12.55 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 1.88 and a beta of 0.57.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Barclays increased their price target on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Finally, Jefferies Financial Group downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Hold” and an average price target of $80.00.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.